Skip to content

April 2026

Anxiety

What April 2026's 5 new studies found, synthesized from the papers below. All Anxiety research →

The synthesis

Synthesized from 2 studies in the library · AI-generated, grounded in the abstracts below

Found by searching the library for Anxiety, generalized anxiety disorder, GAD, panic disorder, anxiety disorder, then ranked by relevance.

Research on anxiety in April 2026 is limited and indirect. One animal study found that ayahuasca reversed chronic stress-induced anxiety-like behavior in zebrafish, suggesting potential anxiolytic effects. However, a large retrospective cohort study found that anxiety disorders are common in individuals with hallucinogen persisting perception disorder (HPPD) and predict its development, indicating a risk factor. No human clinical trials directly testing psychedelics for anxiety were identified in this set.

Confidence in the evidence

Insufficient
  • Only two studies directly address anxiety: one animal model (zebrafish) and one retrospective cohort study on HPPD.
  • The animal study (article_id 28220) is preclinical and cannot be directly extrapolated to humans.
  • The cohort study (article_id 28029) shows an association between anxiety and HPPD, not a therapeutic effect.
  • No human clinical trials or reviews specifically on anxiety treatment with psychedelics were provided.
How we rate confidence

Confidence reflects the strength of the underlying evidence, not whether the result is favorable. It weighs the number and size of studies, their design (randomized trials count for more than observational or single-case work), how consistently they point the same way, and their risk of bias.

Tiers run from Insufficient to High. High is rare in this field: small, early, or open-label studies land lower even when their direction is encouraging.

Evidence by study

Direction is each study's finding relative to your question: Supports, Opposes, No effect, Mixed, or Unclear.

Single exposure to Ayahuasca reverses chronic stress effects on sociability, anxiety, cortisol, and BDNF in zebrafish 2026
Supports

A single exposure to ayahuasca reversed chronic stress-induced anxiety-like behavior in zebrafish, along with restoring sociability and biochemical markers.

preclinical animal study

Characterising the clinical associations of hallucinogen persisting perception disorder: a retrospective cohort study 2026
Opposes

Anxiety disorders were present in 26.2% of HPPD patients before diagnosis, and anxiety predicted HPPD development in psychedelic users (OR 1.5), indicating a risk association.

retrospective cohort study Sample size: 25778

Points of agreement

  • Both studies involve psychedelic substances (ayahuasca, MDMA, psilocybin) and their relationship to anxiety.
  • Both highlight the importance of considering anxiety in the context of psychedelic use.

Conflicts

  • The animal study suggests ayahuasca may reduce anxiety, while the cohort study links psychedelic use to increased anxiety risk in some individuals (HPPD).
  • The studies address different populations (zebrafish vs. humans) and different outcomes (therapeutic vs. adverse), so direct conflict is limited.

Gaps

  • No human clinical trials testing psychedelics for anxiety disorders are included.
  • The durability of any anxiolytic effects from ayahuasca is not addressed.
  • Specific populations (e.g., social anxiety in autism) are mentioned but not empirically tested in the provided studies.
  • Dose-response relationships and long-term safety data are lacking.
Browse these studies in the library